You are here

Abzyme Therapeutics, LLC

Company Information
Address
321 Jones Blvd, Ste 300
Pottstown, PA 19464-3468
United States


http://www.abzymetx.com

Information

DUNS: 962964990

# of Employees: 8


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Antibody Fragments to Improve HIV gp120 Protein Production

    Amount: $299,815.00

    Camelid single domain antibody fragmentsVHHpossess a number of distinctive features including a small sizean elevated stabilityand an ability to recognize epitopes non accessible for conventional anti ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  2. Pemphigus-specific T cell engagers for pemphigus targeted immunotherapy

    Amount: $280,352.00

    ABSTRACTPemphiguspemphigus vulgarisPVand pemphigus foliaceusPFis an acquired autoimmune disease in which IgG antibodies target the keratinocyte desmosomal cadherin proteins desmogleinand desmogleinres ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  3. Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases

    Amount: $299,989.00

    ABSTRACTRetinal neovascular diseases including neovascular age related macular degenerationdiabetic macular edema and retinal vein occlusion are the most vision threatening diseases among the working ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  4. Topic 373: Monoclonal Antibodies to RNA-modifications

    Amount: $299,999.00

    Post-transcriptional RNA modification is quite complex as there are more than sixty known RNA modifications that occur in thousands of RNAs in eukaryotic cells. A number of these RNA modifications hav ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  5. Medical Countermeasure Development for Viral Induced Encephalitis Using Single DomainAntibodies

    Amount: $499,999.06

    Alphaviruses, infection with which may cause encephalitis and death, are recognized as potential biological warfare agents. There are noapproved medical countermeasures against Alphaviruses. In Phase ...

    SBIRPhase II2018Department of Defense Office for Chemical and Biological Defense
  6. Modular antibody engineering to overcome the blood brain barrier

    Amount: $236,646.00

    Abstract Immunotherapy is one of the most promising approaches for treatment of various human diseases including cancers autoimmune and infectious diseases However systemic immunotherapies have be ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  7. Development Of Arginine Linkage Specific Antibodies

    Amount: $224,926.00

    ASBTRACT Arginylation mediated by arginyltransferase ATE is a posttranslational modification that plays a global role in mammals Arginylation is essential for mammalian embryogenesis and regulati ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  8. Human monoclonal antibodies as countermeasures for T-2 mycotoxin

    Amount: $149,964.61

    Mycotoxins are fungal toxins to which exposure frequently results in incapacitation or even in death. Natural outbreaks of mycotoxin poisoningare common worldwide. Due to its physical-chemical propert ...

    SBIRPhase I2016Department of Defense Office for Chemical and Biological Defense
  9. Novel approach for rapid generation of human antibodies to RNA-modifications

    Amount: $224,638.00

    Project Summary It is known that protein activity can be modulated by post translational protein phosphorylation Phospho specific antibodies have greatly advanced understanding of the mechanisms of ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  10. High throughput camelid antibody screening as a drug discovery platform

    Amount: $1,670,345.00

    ABSTRACTMonoclonal antibodies are used for treatment of a wide range of diseases from cancer to infectious diseasesHoweverdevelopment of antibodies with high affinity and specificity is still timecons ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government